Allarity Therapeutics, Inc.
ALLR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,203 | $2,321 | $1,403 | $1,847 |
| G&A Expenses | $0 | $1,812 | $1,633 | $5,470 |
| SG&A Expenses | $1,315 | $1,812 | $1,633 | $5,470 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,518 | $4,133 | $3,036 | $7,317 |
| Operating Income | -$2,518 | -$4,133 | -$3,036 | -$7,317 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$288 | $1,813 | $304 | -$136 |
| Pre-Tax Income | -$2,806 | -$2,320 | -$2,732 | -$7,453 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,806 | -$2,320 | -$2,732 | -$7,453 |
| % Margin | – | – | – | – |
| EPS | -0.19 | -0.149 | -0.245 | -1.021 |
| % Growth | -27.5% | 39.1% | 76% | – |
| EPS Diluted | -0.19 | -0.149 | -0.245 | -1.021 |
| Weighted Avg Shares Out | 14,740 | 15,543 | 11,147 | 7,303 |
| Weighted Avg Shares Out Dil | 14,740 | 15,543 | 11,147 | 7,303 |
| Supplemental Information | – | – | – | – |
| Interest Income | $187 | $237 | $222 | $219 |
| Interest Expense | $57 | $12 | $57 | $75 |
| Depreciation & Amortization | $0 | $12 | $11 | $1 |
| EBITDA | -$2,749 | -$2,296 | -$2,664 | -$7,377 |
| % Margin | – | – | – | – |